{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33","upperLimit":"66","value":"51"}]}],"title":"Matched Related Donors (MRD) n=38"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12","upperLimit":"35","value":"22"}]}],"title":"Matched Unrelated Donors (MUD) n=53"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"39","value":"23"}]}],"title":"Haploidentical related (HAPLO) donors n=33"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"description":"Estimate overall survival rates in participants treated with an alemtuzumab T cell depleted, reduced intensity preparative regimen followed by allogeneic hematopoietic transplantation. Disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates after SCT were estimated using the Kaplan-Meier method. We performed univariate comparisons by using the log-rank test. OS was defined as the period of time between the day of transplantation and death. The following variables were considered as confounders: recipient age, recipient sex, disease (myeloid or lymphoid), disease risk (standard or high), and donor type (MRD, MUD, or HAPLO donor). The percentage of participants surviving 2 years by donor type is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Non-myeloablative Stem Cell Transplant (SCT): Donor will receive Granulocyte colony-stimulating factor (G-CSF) 8 mcg/kg/d subcutaneously twice daily for 4 days, until pheresis is completed or until white blood cells \\> 100,000. Recipients will be premedicated with Benadryl 50 mg intravenously (IV) or orally (PO), and acetaminophen 650 mg PO (or hydrocortisone 50-100 mg IV on first day). The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. The prep regimen for myeloid disease will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The Peripheral Blood Stem Cells (PBSCs) will be infused over 2-4 days. Participant evaluations will occur 2 times per week by physical exam for toxicity through day 45.","id":"OG000","title":"Cohort A & B - Lymphoid & Myeloid Disease"}],"paramType":"NUMBER","populationDescription":"All participants who received transplant. Cohort A (n=62) had acute or chronic leukemia (ALL or CLL), lymphoma, or myeloma. Cohort B (n=62) had acute or chronic myeloid leukemia (AML or CML), myelodysplastic disorder or myeloproliferative disorder. Analysis by type of donor (Matched Unrelated Donor; Matched Related Donor; Haplo-identical).","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}